Gastroesophageal Reflux Disease (GERD) Therapeutics

Gastroesophageal Reflux Disease (GERD) Therapeutics

Global Gastroesophageal Reflux Disease (GERD) Therapeutics Market to Reach US$7.8 Billion by 2030

The global market for Gastroesophageal Reflux Disease (GERD) Therapeutics estimated at US$6.1 Billion in the year 2023, is expected to reach US$7.8 Billion by 2030, growing at a CAGR of 3.6% over the analysis period 2023-2030. Antacids, one of the segments analyzed in the report, is expected to record a 4.4% CAGR and reach US$3.6 Billion by the end of the analysis period. Growth in the H2 Receptor Blockers segment is estimated at 3.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.6 Billion While China is Forecast to Grow at 5.6% CAGR

The Gastroesophageal Reflux Disease (GERD) Therapeutics market in the U.S. is estimated at US$1.6 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.6 Billion by the year 2030 trailing a CAGR of 5.6% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.3% and 3.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.8% CAGR.

Global Gastroesophageal Reflux Disease (GERD) Therapeutics Market – Definition, Key Trends & Drivers Summarized

What Is Gastroesophageal Reflux Disease (GERD) and Why Is It a Significant Health Concern?

Gastroesophageal reflux disease (GERD) is a chronic condition where stomach acid or bile flows back into the esophagus, irritating its lining and leading to symptoms like heartburn, regurgitation, and chest pain. But why is GERD considered a significant health concern? GERD affects millions of people globally and can cause severe discomfort, impact quality of life, and lead to complications like esophagitis, Barrett`s esophagus, and an increased risk of esophageal cancer if left untreated. GERD is primarily managed through lifestyle changes, over-the-counter medications, and prescription drugs. As the prevalence of GERD rises due to factors like obesity, sedentary lifestyles, and poor dietary habits, there is a growing demand for effective therapeutic options. The increasing awareness of the long-term risks associated with untreated GERD is driving the need for innovative therapeutics that provide better symptom control and prevent complications.

How Are Technological Advancements and Innovations Shaping GERD Therapeutics?

Advancements in medical technology and pharmaceutical research are transforming the treatment of GERD, but how are these innovations improving therapeutic options? One of the key trends is the development of proton pump inhibitors (PPIs), which are among the most commonly prescribed medications for GERD. PPIs work by reducing stomach acid production, offering long-term relief from acid reflux symptoms. Newer formulations of PPIs, such as delayed-release capsules and combination therapies, are improving symptom control and patient adherence by offering more convenient dosing schedules and sustained acid suppression throughout the day.

In addition to PPIs, H2 receptor antagonists and antacids are widely used as over-the-counter treatments for mild to moderate GERD symptoms. Recent innovations in H2 blockers include rapid-acting formulations that provide faster relief for patients experiencing acute symptoms. Moreover, new antacid formulations, like liquid gels, offer quicker and more effective neutralization of stomach acid.

Beyond medication, minimally invasive surgical options, such as laparoscopic fundoplication and endoscopic treatments, are gaining traction as alternatives for patients with severe or treatment-resistant GERD. These procedures offer long-term relief by strengthening the lower esophageal sphincter, which helps prevent acid reflux. Furthermore, advancements in diagnostic tools, such as high-resolution esophageal manometry and pH monitoring, are enabling more accurate diagnosis and tailored treatment approaches, improving patient outcomes.

How Are Healthcare Trends and Regulatory Factors Impacting the GERD Therapeutics Market?

What role do healthcare trends and regulatory factors play in shaping the GERD therapeutics market? The rising incidence of lifestyle-related conditions such as obesity and diabetes, which are closely linked to GERD, is driving the demand for effective treatment options. As more people adopt sedentary lifestyles and diets high in processed foods and fats, the prevalence of GERD continues to rise, especially in developed countries. This has led to increased healthcare expenditures on GERD management, including medications, diagnostics, and surgical interventions.

In terms of regulations, government agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) closely monitor the approval of GERD medications to ensure their safety and efficacy. Regulatory bodies are particularly focused on the long-term use of PPIs, as prolonged use has been linked to potential side effects, including nutrient deficiencies and an increased risk of infections. This has spurred pharmaceutical companies to develop safer, more effective therapies with fewer adverse effects, including new PPI formulations and non-PPI medications that target GERD symptoms differently, such as potassium-competitive acid blockers (P-CABs).

The focus on patient-centric healthcare is also influencing the market, as there is growing demand for personalized treatment approaches that consider a patient`s specific symptoms, medical history, and risk factors. Healthcare providers are increasingly adopting a holistic approach to GERD management, integrating lifestyle modifications, pharmacological treatments, and, in some cases, surgical options to optimize patient outcomes. These healthcare trends, combined with regulatory scrutiny, are shaping the development of safer, more effective GERD therapeutics.

What Are the Key Drivers Behind the Growth of the GERD Therapeutics Market?

The growth in the GERD therapeutics market is driven by several key factors, including the rising prevalence of GERD, advancements in pharmacological treatments, and the increasing demand for effective symptom management. One of the primary drivers is the global rise in GERD cases, fueled by factors like obesity, unhealthy diets, aging populations, and increasing stress levels. These factors contribute to the growing need for medications and treatment strategies that can manage GERD symptoms and prevent complications.

Another significant driver is the advancement in drug development, particularly in the creation of more effective and safer proton pump inhibitors (PPIs), H2 receptor antagonists, and novel acid suppression therapies. Pharmaceutical companies are focusing on improving the bioavailability, duration of action, and safety profiles of these drugs to enhance patient compliance and long-term treatment outcomes. Additionally, the rise of combination therapies, where medications are formulated to address multiple aspects of GERD, is gaining popularity as a more comprehensive approach to managing the disease. The increasing awareness of GERD-related complications, such as esophagitis and esophageal cancer, is also contributing to the demand for better diagnostics and personalized treatment options. Patients and healthcare providers are looking for therapeutic solutions that not only alleviate symptoms but also address the root causes of the disease and prevent recurrence. Furthermore, the trend toward minimally invasive surgical treatments for severe or refractory GERD is expanding the scope of treatment options available to patients. These procedures offer long-term relief with fewer side effects compared to long-term medication use, making them an attractive option for patients who do not respond to traditional therapies. Overall, the combination of rising GERD prevalence, advancements in treatment options, and increasing patient awareness is driving the robust growth of the GERD therapeutics market, with significant potential for continued innovation and expansion in the coming years.

Select Competitors (Total 42 Featured) -
  • Abbott
  • AstraZeneca PLC
  • Daewoong Pharmaceutical Co., Ltd
  • Eisai Co., Ltd.
  • GlaxoSmithKline PLC
  • Ironwood Pharmaceuticals, Inc.
  • Johnson & Johnson Services, Inc.
  • Novartis AG
  • Pfizer, Inc.
  • RaQualia Pharma, Inc.
  • Reckitt Benckiser Group PLC
  • SFJ Pharmaceuticals Group
  • SRS Pharmaceuticals Pvt., Ltd
  • Takeda Pharmaceutical Co., Ltd.
Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.


I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Global Economic Update
Gastroesophageal Reflux Disease (GERD) Therapeutics – Global Key Competitors Percentage Market Share in 2024 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Rising Global Prevalence of GERD Drives Demand for Effective Therapeutics to Manage Acid Reflux and Related Symptoms
Increasing Focus on Minimally Invasive and Non-Surgical Treatments Expands Market for GERD Medications Over Surgical Interventions
Technological Advancements in Drug Delivery Systems Propel Growth in Novel Therapeutic Solutions for GERD
Growing Adoption of Over-The-Counter (OTC) Proton Pump Inhibitors (PPIs) and H2 Blockers Expands Market for GERD Self-Medication
Rising Awareness of GERD Complications, Such as Barretts Esophagus, Fuels Demand for Long-Term Therapeutic Management
Increasing Use of GERD Therapeutics in Pediatric and Geriatric Populations Strengthens Demand for Age-Specific Treatment Options
Technological Innovations in Acid Suppression Therapy Propel Development of More Effective PPIs With Improved Pharmacokinetics
Growing Focus on Lifestyle Changes and Dietary Modifications Expands Market for Complementary GERD Management Products and Therapeutics
Rising Demand for Personalized Medicine Drives Innovation in Tailored GERD Treatments Based on Patient-Specific Symptoms and Risk Factors
Increasing Incidence of Obesity and Sedentary Lifestyles Globally Expands Market for GERD Therapeutics Linked to These Risk Factors
Rising Prevalence of Refractory GERD Strengthens Market for Advanced Therapeutics Such as Potassium-Competitive Acid Blockers (P-CABs)
Increasing Awareness of the Risks Associated With Long-Term Use of PPIs Fuels Demand for Alternative GERD Therapies With Fewer Side Effects
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Recent Past, Current & Future Analysis for Gastroesophageal Reflux Disease (GERD) Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 2: World Historic Review for Gastroesophageal Reflux Disease (GERD) Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 3: World 16-Year Perspective for Gastroesophageal Reflux Disease (GERD) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
TABLE 4: World Recent Past, Current & Future Analysis for Antacids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 5: World Historic Review for Antacids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 6: World 16-Year Perspective for Antacids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 7: World Recent Past, Current & Future Analysis for H2 Receptor Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 8: World Historic Review for H2 Receptor Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 9: World 16-Year Perspective for H2 Receptor Blockers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 10: World Recent Past, Current & Future Analysis for Proton Pump Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 11: World Historic Review for Proton Pump Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 12: World 16-Year Perspective for Proton Pump Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 13: World Recent Past, Current & Future Analysis for Pro-Kinetic Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 14: World Historic Review for Pro-Kinetic Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 15: World 16-Year Perspective for Pro-Kinetic Agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 16: World Gastroesophageal Reflux Disease (GERD) Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
III. MARKET ANALYSIS
UNITED STATES
Gastroesophageal Reflux Disease (GERD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
TABLE 17: USA Recent Past, Current & Future Analysis for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 18: USA Historic Review for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 19: USA 16-Year Perspective for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents for the Years 2014, 2024 & 2030
CANADA
TABLE 20: Canada Recent Past, Current & Future Analysis for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 21: Canada Historic Review for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 22: Canada 16-Year Perspective for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents for the Years 2014, 2024 & 2030
JAPAN
Gastroesophageal Reflux Disease (GERD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
TABLE 23: Japan Recent Past, Current & Future Analysis for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 24: Japan Historic Review for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 25: Japan 16-Year Perspective for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents for the Years 2014, 2024 & 2030
CHINA
Gastroesophageal Reflux Disease (GERD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
TABLE 26: China Recent Past, Current & Future Analysis for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 27: China Historic Review for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 28: China 16-Year Perspective for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents for the Years 2014, 2024 & 2030
EUROPE
Gastroesophageal Reflux Disease (GERD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
TABLE 29: Europe Recent Past, Current & Future Analysis for Gastroesophageal Reflux Disease (GERD) Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 30: Europe Historic Review for Gastroesophageal Reflux Disease (GERD) Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 31: Europe 16-Year Perspective for Gastroesophageal Reflux Disease (GERD) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
TABLE 32: Europe Recent Past, Current & Future Analysis for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 33: Europe Historic Review for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 34: Europe 16-Year Perspective for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents for the Years 2014, 2024 & 2030
FRANCE
Gastroesophageal Reflux Disease (GERD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
TABLE 35: France Recent Past, Current & Future Analysis for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 36: France Historic Review for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 37: France 16-Year Perspective for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents for the Years 2014, 2024 & 2030
GERMANY
Gastroesophageal Reflux Disease (GERD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
TABLE 38: Germany Recent Past, Current & Future Analysis for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 39: Germany Historic Review for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 40: Germany 16-Year Perspective for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents for the Years 2014, 2024 & 2030
ITALY
TABLE 41: Italy Recent Past, Current & Future Analysis for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 42: Italy Historic Review for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 43: Italy 16-Year Perspective for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents for the Years 2014, 2024 & 2030
UNITED KINGDOM
Gastroesophageal Reflux Disease (GERD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
TABLE 44: UK Recent Past, Current & Future Analysis for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 45: UK Historic Review for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 46: UK 16-Year Perspective for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents for the Years 2014, 2024 & 2030
SPAIN
TABLE 47: Spain Recent Past, Current & Future Analysis for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 48: Spain Historic Review for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 49: Spain 16-Year Perspective for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents for the Years 2014, 2024 & 2030
RUSSIA
TABLE 50: Russia Recent Past, Current & Future Analysis for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 51: Russia Historic Review for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 52: Russia 16-Year Perspective for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents for the Years 2014, 2024 & 2030
REST OF EUROPE
TABLE 53: Rest of Europe Recent Past, Current & Future Analysis for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 54: Rest of Europe Historic Review for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 55: Rest of Europe 16-Year Perspective for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents for the Years 2014, 2024 & 2030
ASIA-PACIFIC
Gastroesophageal Reflux Disease (GERD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
TABLE 56: Asia-Pacific Recent Past, Current & Future Analysis for Gastroesophageal Reflux Disease (GERD) Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 57: Asia-Pacific Historic Review for Gastroesophageal Reflux Disease (GERD) Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 58: Asia-Pacific 16-Year Perspective for Gastroesophageal Reflux Disease (GERD) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
TABLE 59: Asia-Pacific Recent Past, Current & Future Analysis for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 60: Asia-Pacific Historic Review for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 61: Asia-Pacific 16-Year Perspective for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents for the Years 2014, 2024 & 2030
AUSTRALIA
Gastroesophageal Reflux Disease (GERD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
TABLE 62: Australia Recent Past, Current & Future Analysis for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 63: Australia Historic Review for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 64: Australia 16-Year Perspective for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents for the Years 2014, 2024 & 2030
INDIA
Gastroesophageal Reflux Disease (GERD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
TABLE 65: India Recent Past, Current & Future Analysis for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 66: India Historic Review for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 67: India 16-Year Perspective for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents for the Years 2014, 2024 & 2030
SOUTH KOREA
TABLE 68: South Korea Recent Past, Current & Future Analysis for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 69: South Korea Historic Review for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 70: South Korea 16-Year Perspective for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents for the Years 2014, 2024 & 2030
REST OF ASIA-PACIFIC
TABLE 71: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 72: Rest of Asia-Pacific Historic Review for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 73: Rest of Asia-Pacific 16-Year Perspective for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents for the Years 2014, 2024 & 2030
LATIN AMERICA
Gastroesophageal Reflux Disease (GERD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
TABLE 74: Latin America Recent Past, Current & Future Analysis for Gastroesophageal Reflux Disease (GERD) Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 75: Latin America Historic Review for Gastroesophageal Reflux Disease (GERD) Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 76: Latin America 16-Year Perspective for Gastroesophageal Reflux Disease (GERD) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
TABLE 77: Latin America Recent Past, Current & Future Analysis for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 78: Latin America Historic Review for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 79: Latin America 16-Year Perspective for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents for the Years 2014, 2024 & 2030
ARGENTINA
TABLE 80: Argentina Recent Past, Current & Future Analysis for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 81: Argentina Historic Review for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 82: Argentina 16-Year Perspective for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents for the Years 2014, 2024 & 2030
BRAZIL
TABLE 83: Brazil Recent Past, Current & Future Analysis for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 84: Brazil Historic Review for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 85: Brazil 16-Year Perspective for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents for the Years 2014, 2024 & 2030
MEXICO
TABLE 86: Mexico Recent Past, Current & Future Analysis for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 87: Mexico Historic Review for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 88: Mexico 16-Year Perspective for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents for the Years 2014, 2024 & 2030
REST OF LATIN AMERICA
TABLE 89: Rest of Latin America Recent Past, Current & Future Analysis for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 90: Rest of Latin America Historic Review for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 91: Rest of Latin America 16-Year Perspective for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents for the Years 2014, 2024 & 2030
MIDDLE EAST
Gastroesophageal Reflux Disease (GERD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
TABLE 92: Middle East Recent Past, Current & Future Analysis for Gastroesophageal Reflux Disease (GERD) Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 93: Middle East Historic Review for Gastroesophageal Reflux Disease (GERD) Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 94: Middle East 16-Year Perspective for Gastroesophageal Reflux Disease (GERD) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
TABLE 95: Middle East Recent Past, Current & Future Analysis for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 96: Middle East Historic Review for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 97: Middle East 16-Year Perspective for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents for the Years 2014, 2024 & 2030
IRAN
TABLE 98: Iran Recent Past, Current & Future Analysis for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 99: Iran Historic Review for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 100: Iran 16-Year Perspective for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents for the Years 2014, 2024 & 2030
ISRAEL
TABLE 101: Israel Recent Past, Current & Future Analysis for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 102: Israel Historic Review for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 103: Israel 16-Year Perspective for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents for the Years 2014, 2024 & 2030
SAUDI ARABIA
TABLE 104: Saudi Arabia Recent Past, Current & Future Analysis for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 105: Saudi Arabia Historic Review for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 106: Saudi Arabia 16-Year Perspective for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents for the Years 2014, 2024 & 2030
UNITED ARAB EMIRATES
TABLE 107: UAE Recent Past, Current & Future Analysis for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 108: UAE Historic Review for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 109: UAE 16-Year Perspective for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents for the Years 2014, 2024 & 2030
REST OF MIDDLE EAST
TABLE 110: Rest of Middle East Recent Past, Current & Future Analysis for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 111: Rest of Middle East Historic Review for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 112: Rest of Middle East 16-Year Perspective for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents for the Years 2014, 2024 & 2030
AFRICA
Gastroesophageal Reflux Disease (GERD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
TABLE 113: Africa Recent Past, Current & Future Analysis for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 114: Africa Historic Review for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 115: Africa 16-Year Perspective for Gastroesophageal Reflux Disease (GERD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antacids, H2 Receptor Blockers, Proton Pump Inhibitors and Pro-Kinetic Agents for the Years 2014, 2024 & 2030
IV. COMPETITION

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings